Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Dec 19:59:5-6.
doi: 10.1016/j.euros.2023.11.001. eCollection 2024 Jan.

Establishing a Role for Radical Prostatectomy in Low-volume Metastatic Disease: From Premise to Proof?

Claudia Kesch  1   2 , Giorgio Calleris  1   3 , Benjamin Pradere  1 , Guillaume Ploussard  1
Affiliations
Editorial

Establishing a Role for Radical Prostatectomy in Low-volume Metastatic Disease: From Premise to Proof?

Claudia Kesch et al. Eur Urol Open Sci. .
No abstract available

PubMed Disclaimer

References

    1. Parker C.C., James N.D., Brawley C.D., et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet. 2018;392:2353–2366. doi: 10.1016/S0140-6736(18)32486-3. - DOI - PMC - PubMed
    1. Boevé L.M.S., Hulshof M.C.C.M., Vis A.N., et al. Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: data from the HORRAD trial. Eur Urol. 2019;75:410–418. doi: 10.1016/j.eururo.2018.09.008. - DOI - PubMed
    1. Bossi A., Foulon S., Maldonado X., et al. Prostate irradiation in men with de novo, low-volume, metastatic, castration-sensitive prostate cancer (mCSPC): results of PEACE-1, a phase 3 randomized trial with a 2x2 design. J Clin Oncol. 2023;41(17 Suppl):LBA5000. doi: 10.1200/jco.2023.41.17_suppl.LBA5000. - DOI
    1. Fizazi K., Foulon S., Carles J., et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. Lancet. 2022;399:1695–1707. doi: 10.1016/S0140-6736(22)00367-1. - DOI - PubMed
    1. Dai B., Zhang S., Wan F.N., et al. Combination of androgen deprivation therapy with radical local therapy versus androgen deprivation therapy alone for newly diagnosed oligometastatic prostate cancer: a phase II randomized controlled trial. Eur Urol Oncol. 2022;5:519–525. doi: 10.1016/j.euo.2022.06.001. - DOI - PubMed

Publication types

LinkOut - more resources